Ex-vivo T-cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges

Allogeneic transplantation still remains as standard of care for patients with high-risk hematological malignancies at diagnosis or after relapse. However, GvHD remains yet as the most relevant clinical complication in the early post-transplant period. TCD allogeneic transplant is now considered a valid option to reduce severe GvHD and to provide a platform for cellular therapy to prevent relapse disease or to treat opportunistic infections.

Automated summary

Allogeneic transplantation remains the standard of care for high-risk hematological malignancies, with GvHD being the most relevant clinical complication post-transplant. TCD allogeneic transplant is now considered a valid option to reduce severe GvHD and serve as a platform for cellular therapy.